CELCUITY INC (CELC)

US15102K1007 - Common Stock

15.92  +0.15 (+0.95%)

After market: 15.92 0 (0%)

Fundamental Rating

2

CELC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While CELC seems to be doing ok healthwise, there are quite some concerns on its profitability. CELC has a expensive valuation and it also scores bad on growth.



1

1. Profitability

1.1 Basic Checks

CELC had negative earnings in the past year.
In the past year CELC has reported a negative cash flow from operations.
In the past 5 years CELC always reported negative net income.
In the past 5 years CELC always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of CELC (-33.35%) is better than 68.66% of its industry peers.
The Return On Equity of CELC (-45.63%) is better than 70.55% of its industry peers.
Industry RankSector Rank
ROA -33.35%
ROE -45.63%
ROIC N/A
ROA(3y)-30.27%
ROA(5y)-39.98%
ROE(3y)-39.63%
ROE(5y)-47.6%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CELC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

CELC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CELC has more shares outstanding
Compared to 1 year ago, CELC has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 4.39 indicates that CELC is not in any danger for bankruptcy at the moment.
CELC has a better Altman-Z score (4.39) than 79.62% of its industry peers.
CELC has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
CELC has a Debt to Equity ratio of 0.26. This is in the lower half of the industry: CELC underperforms 70.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 4.39
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 13.43 indicates that CELC has no problem at all paying its short term obligations.
CELC has a better Current ratio (13.43) than 87.67% of its industry peers.
A Quick Ratio of 13.43 indicates that CELC has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 13.43, CELC belongs to the best of the industry, outperforming 87.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.43
Quick Ratio 13.43

1

3. Growth

3.1 Past

CELC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.67%.
EPS 1Y (TTM)-2.67%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q5.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 9.25% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.78%
EPS Next 2Y-13.4%
EPS Next 3Y9.25%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

CELC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.4%
EPS Next 3Y9.25%

0

5. Dividend

5.1 Amount

CELC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CELCUITY INC

NASDAQ:CELC (4/26/2024, 7:00:00 PM)

After market: 15.92 0 (0%)

15.92

+0.15 (+0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap484.76M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.35%
ROE -45.63%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 13.43
Quick Ratio 13.43
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-2.67%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-10.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y